- Home
- AGEN vs HNVR Comparison
AGEN vs HNVR Comparison
Compare AGEN & HNVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AGEN | HNVR |
|---|---|---|
| Founded | 1994 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Commercial Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.2M | 147.6M |
| IPO Year | 1999 | 2022 |
Fundamental Metrics
Financial Performance| Metric | AGEN | HNVR |
|---|---|---|
| Price | $3.38 | $21.51 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | $14.50 | ★ $24.50 |
| AVG Volume (30 Days) | ★ 486.5K | 4.2K |
| Earning Date | 03-16-2026 | 04-22-2026 |
| Dividend Yield | N/A | ★ 1.88% |
| EPS Growth | ★ 100.00 | N/A |
| EPS | N/A | ★ 1.00 |
| Revenue | ★ $42,877,086.00 | N/A |
| Revenue This Year | $61.42 | $35.49 |
| Revenue Next Year | N/A | $8.61 |
| P/E Ratio | ★ $8.89 | $21.29 |
| Revenue Growth | ★ 89.95 | N/A |
| 52 Week Low | $1.38 | $18.31 |
| 52 Week High | $7.34 | $24.36 |
Technical Indicators
Market Signals| Indicator | AGEN | HNVR |
|---|---|---|
| Relative Strength Index (RSI) | 49.59 | 45.59 |
| Support Level | $2.91 | $20.44 |
| Resistance Level | $4.72 | $22.41 |
| Average True Range (ATR) | 0.27 | 0.51 |
| MACD | -0.01 | 0.12 |
| Stochastic Oscillator | 38.97 | 53.23 |
Price Performance
Historical ComparisonAbout AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About HNVR Hanover Bancorp Inc.
Hanover Bancorp Inc is a United States-based banking company. It offers a full range of financial services and employs a complete suite of consumer and commercial banking products and services, including multi-family and commercial mortgages, residential loans, business loans, and lines of credit.